Objective: To evaluate the effectiveness of a Sepsis Fast Track (SFT) programme initiated at a regional referral hospital in Thailand in January 2015.
Design: A retrospective analysis using the data of a prospective observational study (Ubon-sepsis) from March 2013 to January 2017.
Setting: General medical wards and medical intensive care units (ICUs) of a study hospital.
Participants: Patients with community-acquired sepsis observed under the Ubon-sepsis cohort. Sepsis was defined as modified Sequential Organ Failure Assessment (SOFA) Score ≥2.
Main Exposure: The SFT programme was a protocol to identify and initiate sepsis care on hospital admission, implemented at the study hospital in 2015. Patients in the SFT programme were admitted directly to the ICUs when available. The non-exposed group comprised of patients who received standard of care.
Main Outcome: The primary outcome was 28-day mortality. The secondary outcomes were measured sepsis management interventions.
Results: Of 3806 sepsis patients, 903 (24%) were detected and enrolled in the SFT programme of the study hospital (SFT group) and 2903 received standard of care (non-exposed group). Patients in the SFT group had more organ dysfunction, were more likely to receive measured sepsis management and to be admitted directly to the ICU (19% vs 4%). Patients in the SFT group were more likely to survive (adjusted HR 0.72, 95% CI 0.58 to 0.88, p=0.001) adjusted for admission year, gender, age, comorbidities, modified SOFA Score and direct admission to the ICUs.
Conclusions: The SFT programme is associated with improved sepsis care and lower risk of death in sepsis patients in rural Thailand, where some critical care resources are limited. The survival benefit is observed even when all patients enrolled in the programme could not be admitted directly into the ICUs.
Trial Registration Number: NCT02217592.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896572 | PMC |
http://dx.doi.org/10.1136/bmjopen-2020-041022 | DOI Listing |
J Magn Reson Imaging
November 2024
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Background: The risk of biochemical recurrence (BCR) in prostate cancer (PCa) is typically assessed using D'Amico score. However, iron and fat content in PCa are closely related to tumor cell proliferation and the risk of BCR may be estimated using multiparametric MRI (mpMRI).
Purpose: To noninvasively estimate fat and iron content in PCa and to evaluate their utility in enhancing D'Amico scores for predicting BCR in PCa patients.
Contemp Clin Trials
December 2024
Fred Hutchinson Cancer Center, Division of Public Health Sciences, Seattle, WA, USA. Electronic address:
Globally, cigarette smoking results in over 8 million premature annual deaths. Addressing this issue requires high-impact, cost-effective population-level interventions for smoking cessation. Conversational chatbots offer a potential solution given the recent advancements in machine learning and large language models.
View Article and Find Full Text PDFNeurooncol Adv
September 2024
Brain Tumor Center, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
Background: Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients with refractory or recurrent disease after previous surgery or radiotherapy, there is no effective treatment.
View Article and Find Full Text PDFLab Invest
November 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. Electronic address:
Trop Anim Health Prod
October 2024
Department of Veterinary Medicine, Federal University of Juiz de Fora, Rua José Lourenço Kelmer, Juiz de Fora, Minas Gerais, 36036-900, Brazil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!